Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Metrics to compare | 1PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1PODDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 93.3x | 23.8x | −0.7x | |
PEG Ratio | −2.45 | 0.00 | 0.00 | |
Price/Book | 15.1x | 6.8x | 2.6x | |
Price / LTM Sales | 9.3x | 4.4x | 3.4x | |
Upside (Analyst Target) | - | 11.8% | 39.3% | |
Fair Value Upside | Unlock | 26.0% | 5.7% | Unlock |